Get the Stockscreener App
0.46
1.21%
+0.0055
Cadrenal Therapeutics Inc stock is currently priced at $0.46, with a 24-hour trading volume of 29,991.
It has seen a +1.21% increased in the last 24 hours and a -25.69% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4485 pivot point. If it approaches the $0.4659 resistance level, significant changes may occur.
Previous Close:
$0.4545
Open:
$0.45
24h Volume:
29,991
Market Cap:
$7.28M
Revenue:
-
Net Income/Loss:
$-8.36M
P/E Ratio:
-0.656
EPS:
-0.7012
Net Cash Flow:
$-3.53M
1W Performance:
+8.59%
1M Performance:
-25.69%
6M Performance:
+4.55%
1Y Performance:
-64.20%
1D Range:
$0.45
$0.4699
52W Range:
$0.36
$3.14
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904 300 0701
Address
822 A1A North, Suite 320, Ponte Vedra
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Benzinga
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Cadrenal Therapeutics Inc (CVKD) Net Income 2024
CVKD net income (TTM) was -$8.36 million for the quarter ending December 31, 2023.
Cadrenal Therapeutics Inc (CVKD) Cash Flow 2024
CVKD recorded a free cash flow (TTM) of -$3.53 million for the quarter ending December 31, 2023.
Cadrenal Therapeutics Inc (CVKD) Earnings per Share 2024
CVKD earnings per share (TTM) was -$0.69 for the quarter ending December 31, 2023.
Cadrenal Therapeutics Inc Stock (CVKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MURPHY JOHN RAYMOND | Director |
Oct 04 '23 |
Buy |
0.70 |
17,331 |
12,132 |
612,123 |
| Pham Quang X | CEO and Chairman |
Sep 05 '23 |
Buy |
0.90 |
40,000 |
36,188 |
3,410,000 |
| Pham Quang X | CEO and Chairman |
Sep 01 '23 |
Buy |
0.91 |
70,000 |
63,945 |
3,370,000 |
About Cadrenal Therapeutics Inc
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
0.49%
4.00%
Cap:
|
Volume (24h):